(NASDAQ:OKYO), LONDON and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, is pleased to announce that […]
KINGSTOWN, St. Vincent and the Grenadines, Jan. 22, 2025 (GLOBE NEWSWIRE) — WOO X, a leading global centralized crypto trading platform known for its innovative trading solutions, has launched an exclusive reward event, with 0.1 bps of all spot and perpetual trading volumes allocated directly to WOO stakers from January 23 to February 6. “This
(NasdaqGM:CHRS), – Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor activity was observed across both viral and non-viral etiologies – – Data support continued evaluation of casdozokitug with VEGF and PD-(L)1 blockade in HCC – – Randomized
(NasdaqGM:AXSM), NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the fourth quarter and full year of 2024 on Tuesday, February 18, 2025, before the opening
(NYSE MKT:CATX), SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that an abstract on updated interim results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET (NCT05636618) has been accepted as
(NasdaqGM:NRIX), SAN FRANCISCO, Jan. 22, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointment of John Northcott as chief commercial officer (CCO). Mr. Northcott has over 20 years of commercial experience, including
(NASDAQ:HSDT), –PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy on gait deficit improvement in people with Multiple Sclerosis– –Statistically significant findings in DGI (Dynamic Gait Index) during Phase 1 and Phase 2 among the 38 subjects who completed the treatment protocol showing a total mean improvement of 5.00 (4.1
(TSX-V:NEXG),(OTC US:NXGCF),(OTCQX:NXGCF), TORONTO, Jan. 22, 2025 (GLOBE NEWSWIRE) — NexGold Mining Corp. (TSXV: NEXG; OTCQX: NXGCF) (“NexGold” or the “Company“) is pleased to announce it has commenced drilling on the Goldboro Deposit at the Company's Goldboro Project in Nova Scotia (“Goldboro“). The drill program, which comprises up to 25,000 metres, is primarily designed to infill
(TSX-V:KRY), Highlights Large-scale, C$20M technical program to be completed during 2025. Transforming Haib into a top-tier, high quality, low risk copper development project. Multi-phase, >55,000m drill program to be completed during 2025. Drilling underway with 3 drill rigs ramping up to 6 rigs and double shifting to maximize drilling rates. Phase 2 metallurgical test work
(TSX-V:HI),(OTC US:HDRSF),(Other OTC:HDRSF), VANCOUVER, British Columbia, Jan. 22, 2025 (GLOBE NEWSWIRE) — Highland Copper Company Inc. (TSXV: HI; OTCQB: HDRSF) (“Highland Copper” or the “Company”) is pleased to announce the commencement of a new drilling program aimed at extracting samples for advanced metallurgical testing. This initiative marks a significant step forward in optimizing project economics